概要
子宫内膜癌是最常见的子宫癌类型,占子宫癌病例的90%。本文通过临床研究,检测子宫内膜癌患者标本中雌激素受体（ER）和DNA复制ATP依赖性解旋酶/核酸酶（DNA2）的表达,并分析两者之间的关系。通过细胞培养实验研究ER调控DNA2表达的机制,证实其与PI3K-AKT通路有关。研究还发现,使用短发夹RNA（shRNA）特异性靶向降低Ishikawa中DNA2的表达,会导致细胞增殖和克隆形成能力降低。总的来说,本研究证实了DNA2作为治疗靶点的可行性,并证明抑制DNA2可使Ishikawa对喜树碱（CPT）化疗增敏。我们的发现为DNA2的潜在机制提供了新的见解,这将有助于开发与子宫内膜癌诊断和治疗相关的新方法。
This is a preview of subscription content, log in via an institution to check access.
References
Bean JR, Hosford SR, Symonds LK, et al., 2015. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+breast cancer. Breast Cancer Res Treat, 149(1):69–79. https://doi.org/10.1007/s10549-014-3201-6
Constantine GD, Kessler G, Graham S, et al., 2019. Increased incidence of endometrial cancer following the women’s health initiative: an assessment of risk factors. J Womens Health (Larchmt), 28(2):237–243. https://doi.org/10.1089/jwh.2018.6956
Duan L, Calhoun S, Shim D, et al., 2021. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol, 13(6):433–444. https://doi.org/10.1093/jmcb/mjab018
Gao CX, Shi JM, Zhang JX, et al., 2022. Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(2):164–170. https://doi.org/10.1631/jzus.B2100392
Han YY, Zhang ZY, Wang Z, et al., 2021. Increased expression of DNA2 was linked to poor prognosis in breast cancer. Dis Markers, 2021:8860728. https://doi.org/10.1155/2021/8860728
Hasson SP, Rubinek T, Ryvo L, et al., 2013. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway. Breast Care (Basel), 8(4):248–255. https://doi.org/10.1159/000354757
Jia PP, Junaid M, Ma YB, et al., 2017. Role of human DNA2 (hDNA2) as a potential target for cancer and other diseases: a systematic review. DNA Repair (Amst), 59:9–19. https://doi.org/10.1016/j.dnarep.2017.09.00
Li CH, Wang CH, 2021. LG-ESSs and HG-ESSs: underlying molecular alterations and potential therapeutic strategies. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(8):633–646. https://doi.org/10.1631/jzus.B2000797
Luo J, Song ZM, Zhang T, et al., 2022. Upregulation of h-TERT and Ki-67 in ectopic endometrium is associated with recurrence of endometriosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(2):158–163. https://doi.org/10.1631/jzus.B2100502
Morice P, Leary A, Creutzberg C, et al., 2016. Endometrial cancer. Lancet, 387(10023):1094–1108. https://doi.org/10.1016/s0140-6736(15)00130-0
Setiawan VW, Yang HP, Pike MC, et al., 2013. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol, 31(20):2607–2618. https://doi.org/10.1200/JCO.2012.48.2596
Strauss C, Kornowski M, Benvenisty A, et al., 2014. The DNA2 nuclease/helicase is an estrogen-dependent gene mutated in breast and ovarian cancers. Oncotarget, 5(19): 9396–9409. https://doi.org/10.18632/oncotarget.2414
Thakar T, Leung W, Nicolae CM, et al., 2020. Ubiquitinated-PCNA protects replication forks from DNA2-mediated degradation by regulating Okazaki fragment maturation and chromatin assembly. Nat Commun, 11:2147. https://doi.org/10.1038/s41467-020-16096-w
Ulrich LSG, 2011. Endometrial cancer, types, prognosis, female hormones and antihormones. Climacteric, 14(4):418–425. https://doi.org/10.3109/13697137.2010.550974
Vassard D, Schmidt L, Glazer CH, et al., 2019. Assisted reproductive technology treatment and risk of ovarian cancer—a nationwide population-based cohort study. Hum Reprod, 34(11):2290–2296. https://doi.org/10.1093/humrep/dez165
Zheng L, Zhou M, Guo ZG, et al., 2008. Human DNA2 is a mitochondrial nuclease/helicase for efficient processing of DNA replication and repair intermediates. Mol Cell, 32(3):325–336. https://doi.org/10.1016/j.molcel.2008.09.024
Acknowledgments
This work was supported by the General Projects of Medical and Health Science and Technology Plan in Zhejiang Province (No. 2020KY433), China.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Data availability statement
All data generated or analyzed during this study are included in this published article and its supplementary information files.
Author contributions
All authors contributed to the study conception and design. Xinyan WANG and Xiuling XU designed the experiment. Ting ZHANG and Yang JIN performed the study. Sheng XU and Lifeng CHEN drafted the manuscript. Yucheng LAI and Ling ZHANG analyzed data. Ruolang PAN and Yan YU designed the experiment, revised the manuscript, and monitored the project progression. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.
Compliance with ethics guidelines
Xinyan WANG, Xiuling XU, Ting ZHANG, Yang JIN, Sheng XU, Lifeng CHEN, Yucheng LAI, Ling ZHANG, Ruolang PAN, and Yan YU declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. Additional informed consent was obtained from all patients for whom identifying information is included in this article. This study was granted by the Ethics Committee of Zhejiang Provincial People’s Hospital (November 9, 2019; No. 2019KY204).
Supplementary information
Figs. S1–S4
Supplementary information
Rights and permissions
About this article
Cite this article
Wang, X., Xu, X., Zhang, T. et al. Estrogen upregulates DNA2 expression through the PI3K-AKT pathway in endometrial carcinoma. J. Zhejiang Univ. Sci. B 24, 262–268 (2023). https://doi.org/10.1631/jzus.B2200436
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2200436